A preliminary analysis of microRNA as potential clinical biomarker for XXXX .

@entity1 @entity11216 @entity61459 @entity31611 @entity7762 @entity161 @entity24341 @entity68191 @entity12333 @entity68048
UNASSIGNED: MicroRNAs (miRNA, @entity11216 ) have been implicated as promising blood-based biomarkers for @entity161 @entity1 . This study aimed to clinically validate miRNA as potential @entity161 biomarkers. Plasma levels of 10 miRNAs were analyzed using qPCR in a cohort of 61 @entity161 @entity1 and 62 normal controls, as well as 25 @entity1 particularly selected for a six-week antipsychotic treatment course. Positive And Negative Syndrome Scale (PANSS), Global Assessment Scale (GAS) and Clinical Global Impression (CGI) were administered to assess the clinical symptoms. The results demonstrated that a panel of miRNAs consisting of @entity68191 , @entity11216 -181b, @entity7762 , @entity68048 and @entity12333 had significantly increased expression levels with significant combined diagnostic value (AUC:0.713; sensitivity:35.5%; specificity:90.2%). In response to pharmacological treatment, expression levels of @entity24341 , @entity11216 -181b, @entity61459 and @entity68191 were significantly decreased. In addition, the improvement of clinical symptomatology was significantly correlated with the changes of @entity24341 , @entity11216 -181b, @entity31611 and @entity68191 expression levels. Furthermore, the decreases of plasma levels of @entity24341 and @entity61459 were significantly greater in high-effect subgroup than those in low-effect subgroup after six-week treatment course. We conclude that @entity68191 , @entity11216 -181b, @entity7762 , @entity68048 and @entity12333 combined as a panel are potentially useful non-invasive biomarkers for @entity161 diagnosis. Markers @entity24341 , @entity11216 -181b, @entity68191 and @entity61459 are potential indicators for symptomatology improvements, treatment responses and prognosis for @entity161 @entity1 .    2015 Wiley Periodicals, Inc.
